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LETTERS TO EDITOR 
in life and beliefs should be considered at par 
with the functional variables. Thus how a patient 
judges the outcome and how the outcomes 
influences the health related quality of life is as 
important as clinician's judgement of prognosis. 
Hence considering a high prevalence 
(25%) of depression amongst the cancer patients 
we feel the presence of a psychiatrist, 
psychoanalyst alongwith the surgeon to 
completely evaluate the patient preoperatively. 
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CATATONIA : NEED FOR CLARIFICATION 
Sir, 
Payee et al.(1999) have confirmed 
contemporary opinion that lorazepam and 
electroconvulsive therapy are effective 
treatments for the catatonic syndrome 
irrespective of the etiology of the syndrome 
(Petrides & Fink, 1999). Two issues in their paper 
however beg clarification : 
1. At several places in the abstract and text, the 
authors aver that the duration of catatonia did 
not predict outcome with lorazepam; however, 
their table shows that the greater duration of 
pretreatment catatonia in lorazepam 
nonresponders (as compared with responders) 
was statistically significant. Which conclusion is 
correct? 
2. The authors do not discuss their patients' 
tolerance of lorazepam, the duration of 
lorazepam therapy specifically in treatment 
responders, and the experience of withdrawal 
of lorazepam after successful as well as 
unsuccessful therapy. These are important 
issues as high dose benzodiazepines are not 
always well tolerated, and as these drugs often 
occasion unpleasant withdrawal symptoms at the 
time of discontinuation. 
The authors' response to these issues 
would be helpful. 
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REPLY 
Sir, 
I am grateful to Dr. Chittaranjan Andrade 
for pointing out the error in Table-2 of our article 
titled "Catatonic Syndrome : Treatment 
Response to Lorazepam". Under duration of 
catatonia the mean rank score of responders 
should read as 22.85 and not as 12.85. The 
duration of catatonia was not found to be a 
significant predictor. 
Patients irciudsd under the study were 
subjected to a detailed clinical examination and 
appropriate investigations to rule out organicity. 
Majority of patients (n=16) responded to 
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